Loading
Life sciences · Journal article
Pharmaceutics · August 14, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic review synthesizing preclinical evidence that bergapten activates multiple apoptotic, autophagy, and antioxidant pathways in cancer cell and animal models. Clinical translation remains limited by absent human pharmacokinetic data, poor aqueous solubility, and the complete lack of human efficacy trials, making this a systems-level hypothesis rather than evidence for clinical use.
Narrative review. Preclinical studies across diverse malignancies; no human subjects studied.
Bergapten activates mitochondrial apoptosis via Bax/Bcl-2 modulation and caspase cascades in preclinical models Induces cell cycle arrest through p53–p21 signaling and suppresses PI3K/Akt/mTOR and NF-κB pathways Reverses multidrug resistance through ABC transporter modulation and exhibits context-dependent photoactivated cytotoxicity
Review contains no human clinical trial data, pharmacokinetic measurements in humans, or efficacy outcomes Incomplete human pharmacokinetic data explicitly acknowledged as a barrier to clinical translation
Bergapten has no established clinical efficacy in humans and should not be used outside investigational settings. The mechanistic promise of preclinical work is not sufficient to guide clinical practice until human pharmacokinetic data and efficacy trials are completed.
This is a mechanistic review of preclinical evidence for bergapten in cancer, synthesizing in vitro and animal studies without human clinical data or efficacy trials to support therapeutic translation.
As stated by the source record.
Bergapten has no established clinical efficacy in humans and should not be used outside investigational settings. The mechanistic promise of preclinical work is not sufficient to guide clinical practice until human pharmacokinetic data and efficacy trials are completed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Bergapten is a plant-derived linear furanocoumarin widely distributed in Rutaceae and Apiaceae species and increasingly recognized for its multifunctional anticancer potential. This review critically synthesizes current evidence on bergapten’s biosynthesis, physicochemical and pharmacokinetic properties, anti-inflammatory and antioxidant pharmacodynamics, and mechanistic antitumor activity, highlighting its translational relevance within pharmaceutical development. Preclinical studies across diverse malignancies demonstrate pleiotropic anticancer effects. Mechanistically, bergapten activates mitochondrial apoptosis via Bax/Bcl-2 modulation and caspase cascades, induces cell cycle arrest through p53–p21 signaling, and suppresses PI3K/Akt/mTOR and NF-κB pathways. Additional effects include PTEN-mediated autophagy induction, interference with metabolic reprogramming, reversal of multidrug resistance through ABC transporter modulation, and context-dependent photoactivated cytotoxicity. Beyond direct tumor cell targeting, bergapten attenuates pro-inflammatory mediators and regulates redox homeostasis through downregulation of NOX4-derived ROS and activation of Nrf2-driven antioxidant defenses, addressing the redox–inflammatory axis implicated in carcinogenesis. Despite promising mechanistic depth, clinical translation is limited by incomplete human pharmacokinetic data and poor aqueous solubility. Nanotechnology-enabled delivery systems and structural derivatives offer strategies to enhance bioavailability and therapeutic index. Overall, bergapten emerges as a systems-level phytochemical candidate warranting further translational investigation in oncology.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.